In these settings, the use of Jak2 inhibitors would be expected to limit or reduce splenomegaly, thereby preventing or delaying the need for splenectomy and indirectly improving the management of anemia and iron overload by reducing the rate of blood transfusions. This evidence concerns the gene JAK2 and Splenomegaly.